- DaVita
- Overview
- Last Modified:
- July 14, 2025
- Company type:
- Public
- Industry:
- Healthcare
- Verified:
- No
- No of Employees:
- 50 001 - 100 000
- Stock Code:
- DVA
- Download
- Signed Health Status Declaration Form
- Turnover $50m + ?:
- Yes
- Headquarters:
- Denver, Colorado, United States
- Public Interest Score:
- 750+
- DaVita
- General Information
Description
DaVita Inc (DaVita) provides dialysis services and integrated health care management services. The company caters to patients with chronic kidney failure and end-stage renal disease (ESRD). It offers various ancillary services, including therapy services, disease management services, vascular access services, ESRD clinical research programs and physician services. The company operates through a network of outpatient dialysis centres in hospitals and related laboratory services. It has an operational presence in Arizona, California, Nevada, Florida, New Mexico, and Colorado. DaVita is headquartered in Denver, Colorado, the US.
qone: No, qtwo: No, qthree: No, qfour: No, qfive: Yes, qsix: No
Barbara Desoer:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Jason Hollar:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Gregory Moore:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Dennis Pullin:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Javier Rodriguez:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Adam Schechter:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Wendy Schoppert:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Phyllis Yale:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Subsribe/ Login to view details on company risk rating
5 Benchmark > 4 Excellent > 3Â Good > 2 Caution > 1 Risk
- Company Information
- Company System Number:
- 15033
- Founded Year:
- 1979
- Registration Number:
- 51 0354549
- Country:
- United States of America
- Stock Exchanges:
-
- New York Stock Exchange
- Financial year end:
- December
- No. of Countries operations:
- 1
- Company Status:
- In Business
- Industry Sub Category:
- Pharmaceuticals and Healthcare
- Date listed on Stock Exchange:
- 31/10/1995
- Contact Information
- Business operation:
- Providing integrated care to help people better manage their kidney disease. Investing in, developing and launching products, solutions and businesses that improve patient care. Conducting clinical trial services across the spectrum of pharmaceutical and medical device development since 1985.
- Primary office:
- 2000 16th St, Denver, Colorado, 80202-5158
- Additional Information
- Listed?:
- Yes
- Company secretary:
- Scott Gruber
- Reporting currency:
- USD
- ISIN number (12 digit):
NYSE
US23918K1088- Authorised shares:
- 88 824 000
- Issued shares:
- 90 411 000
- No of shareholders:
- 1001 and more shareholders
- No of shareholders holding 20%:
- 1 shareholder
- Number of shares traded
- Per Year:
- Per Quarter:
- Per Month:
Shareholders holding 5% +
For a comprehensive list, please contact InsidEntity.
Credit Rating
| Name | Logo | Country | Headquarters | Rating |
|---|---|---|---|---|
| S&P Global Ratings | ![]() | United States of America | New York | BBB- |
| Moody's Financial Services | ![]() | United States of America | New York | Ba2 |
Countries Operations/ Offices
Company Directors
Jason M.
ExecutiveAdam H
ExecutiveWendy
Non Executive
Directors Tenure
Director Experience
Company Auditors
KPMG
Company Past Directors
Company Committees
|
Committee
|
Abbreviation
|
|---|---|
|
Supervisory Board
|
SB
|
|
Board
|
BD
|
|
Risk & Compliance
|
RC
|
|
Audit
|
AU
|
|
Remuneration
|
RE
|
|
Capital investment
|
CI
|
|
Industry Specific
|
IS
|
|
Nominations & Governance
|
NG
|
|
Health, Safety & Environment
|
HS
|
|
Social & Ethics
|
SE
|
|
Technology
|
TE
|
|
Executive
|
EX
|
|
Other
|
OT
|



